RxSight, Inc. — Form 8-K
Filed July 6, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 58/100
What the filing says
RxSight reported Q2 2026 preliminary revenue of $32–34M (including $5–7M from new Alcon collaboration on presbyopia-correcting IOLs) and 24,917 LAL unit sales. Full-year 2026 sales guidance lowered to $110–120M (from $120–135M), though total revenue raised to $140–160M including $30–40M collaboration revenue. Gross margin improved to 73–75% (from 70–72%). Cash position: ~$209M as of June 30, 2026.
Why this rating
Sales miss (guidance cut ~8–17%) offsets collaboration upside; collaboration adds ~$30–40M (~6–8% of revised revenue) but on terms unknown. Material but not trajectory-breaking given strong cash and gross margin improvement.
See more from July 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.